Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

@article{Raymond2008PhaseIS,
  title={Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.},
  author={Eric Raymond and Alba A Brandes and Christian Dittrich and Pierre Fumoleau and Bruno Coudert and Paul M. J. Clement and Marc Paul Frenay and Roy Rampling and Roger Stupp and Johan M. Kros and Michael C Heinrich and Thierry Gorlia and Denis Lacombe and Martin J. van den Bent},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 28},
  pages={4659-65}
}
PURPOSE To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. PATIENTS AND METHODS This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

Similar Papers

Loading similar papers…